``
HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 01, January 2019 – Taiwan medical tourism - Combining medical travel and tourist destination       » New breast cancer drug now available in China       » Chinese scientists make important cancer finding       » Japan's plan to revolutionise healthcare sector with tech       » GSK to buy oncology drugmaker Tesaro for US$5.1 billion       » There is hope for anticancer vaccines      
INSIDE INDUSTRY
Illumina Launches iSeq 100 Sequencing System
Industry-leading sequencing technology for under $20K

Illumina, Inc. announced the launch of the iSeqTM 100 Sequencing System. The new, next-generation sequencing (NGS) system delivers exceptional data accuracy, at a low capital cost, making Illumina technology available to virtually any lab. The combination of the company's proven sequencing by synthesis (SBS) chemistry, along with the complementary metal-oxide-semiconductor (CMOS) detection technology, represents an entirely different configuration that delivers highly accurate data at substantially lower capital costs. The iSeq 100 is the first system with this architecture and has a U.S. list price of $19,900.

Measuring one cubic foot in size, the iSeq 100 delivers NGS discovery power in the most compact format of any Illumina sequencer to date. The iSeq 100 represents another step toward establishing NGS as a standard for discovery research and routine genomic testing for a wide range of customers, markets and applications.

"The iSeq 100 offers robustness and reliability for a broad range of applications ranging from germline and somatic tumor profiling to 16S microbial analysis and targeted gene expression," said Francis deSouza, President and Chief Executive Officer at Illumina

"The addition of the iSeq 100 has great potential to transform infectious disease surveillance," said Dr. Pardis Sabeti, Professor of Immunology and Infectious Disease at Harvard T.H. Chan School of Public Health and a Broad Institute Member. "We anticipate that our lab researchers will use it to focus on infectious disease monitoring.”

Illumina will continue to develop the iSeq architecture further expanding output and reducing run time. These future improvements will open new markets and applications, such as rapid microbiome sequencing, testing for foodborne pathogens and monitoring hospital acquired infections.

Click here for the complete issue.

NEWS CRUNCH  
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy